Phase III clinical trial - Appareil pulmonaire

MS200647-0005
Appareil pulmonaire
Ouvert depuis le: 09.22.2021
Site: Paris
Public cible
Adulte
A Multicenter, Double Blind, Randomized,Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer· Protocol MS200647-0005
Description de l'essai

M7824 (MSB0011359C) is designed to block the PD-1/PD-L1 pathway and to trap transforming growth factor ß (TGFß) in the tumor microenvironment, thereby blocking two non-overlapping pathways that are associated with defective immune response in tumors (Mariathasan 2018). Both pathways are known to be induced by radiation. Multiple murine tumor models have shown an upregulation of PD-L1 expression in microenvironment after radiation (Deng 2014, Dovedi 2014). The upregulation of PD-L1 expression can be further enhanced by TGF blockade (Vanpouille-Box 2015) supporting the hypothesis that combining M7824 with radiotherapy will likely be effective regardless of the initial PD-L1 status of the tumor.